TGFB1 and neoplasm: Results for TGF-β gene expression in the tumor microenvironment showed that after 4 weeks of oral administration with cyclophosphamide, there was a significant decrease compared to 2 and 4 mg glucomannan and the PBS group (p = 0.0079).